Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Judge

Showing results (221-230 of 230) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 230 results.
Journal of Medicinal Chemistry|May 2, 2015
Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and SelectivityMilan Bruncko, Le Wang, George S Sheppard, et al.
Journal of Medicinal Chemistry|February 14, 2015
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivityMilan Bruncko, Le Wang, George S Sheppard, et al.
Molecular Cancer Therapeutics|March 20, 2024
Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell LymphomaJoshua P Plotnik, Adam E Richardson, Haopeng Yang, et al.
Communications Medicine|October 25, 2023
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patientsJunichiro Yuda, Christine Will, Darren C Phillips, et al.
Nature Cancer|March 8, 2022
An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapySarah Chan, Nicole Belmar, Sun Ho, et al.
Molecular Cancer Therapeutics|March 31, 2021
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy VolunteersAhmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.
Journal of Medicinal Chemistry|November 3, 2018
Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug DesignAdrian D Hobson, Russell A Judge, Ana L Aguirre, et al.
ACS Medicinal Chemistry Letters|October 15, 2014
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo ActivityZhi-Fu Tao, Lisa Hasvold, Le Wang, et al.
Science Advances|October 4, 2024
BCL-X<sub>L</sub>-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitorsAndrew S Judd, Bhupinder Bawa, Wayne R Buck, et al.
Pageof 23

Showing results (221-230 of 230) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 230 results.
Journal of Medicinal Chemistry|May 2, 2015
Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and SelectivityMilan Bruncko, Le Wang, George S Sheppard, et al.
Journal of Medicinal Chemistry|February 14, 2015
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivityMilan Bruncko, Le Wang, George S Sheppard, et al.
Molecular Cancer Therapeutics|March 20, 2024
Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell LymphomaJoshua P Plotnik, Adam E Richardson, Haopeng Yang, et al.
Communications Medicine|October 25, 2023
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patientsJunichiro Yuda, Christine Will, Darren C Phillips, et al.
Nature Cancer|March 8, 2022
An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapySarah Chan, Nicole Belmar, Sun Ho, et al.
Molecular Cancer Therapeutics|March 31, 2021
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy VolunteersAhmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.
Journal of Medicinal Chemistry|November 3, 2018
Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug DesignAdrian D Hobson, Russell A Judge, Ana L Aguirre, et al.
ACS Medicinal Chemistry Letters|October 15, 2014
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo ActivityZhi-Fu Tao, Lisa Hasvold, Le Wang, et al.
Science Advances|October 4, 2024
BCL-X<sub>L</sub>-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitorsAndrew S Judd, Bhupinder Bawa, Wayne R Buck, et al.
Pageof 23